Top News

July 18, 2023

Vita Therapeutics Collaborates with MilliporeSigma to Advance Preclinical Program for Vita’s Preclinical Cell Therapy for Limb-Girdle Muscular Dystrophy (LGMD2A)

October 12, 2022

Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers

March 22, 2022

Vita Therapeutics Bolsters Leadership to Advance Multiple Technology Platforms

July 23, 2021

Vita Therapeutics receives Orphan Drug Designation from FDA for new novel treatment